EP1140171A4 - Methods and products for regulating lectin complement pathway associated complement activation - Google Patents

Methods and products for regulating lectin complement pathway associated complement activation

Info

Publication number
EP1140171A4
EP1140171A4 EP99967362A EP99967362A EP1140171A4 EP 1140171 A4 EP1140171 A4 EP 1140171A4 EP 99967362 A EP99967362 A EP 99967362A EP 99967362 A EP99967362 A EP 99967362A EP 1140171 A4 EP1140171 A4 EP 1140171A4
Authority
EP
European Patent Office
Prior art keywords
products
methods
pathway associated
complement
regulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99967362A
Other languages
German (de)
French (fr)
Other versions
EP1140171A1 (en
Inventor
Gregory L Stahl
Charles D Collard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of EP1140171A1 publication Critical patent/EP1140171A1/en
Publication of EP1140171A4 publication Critical patent/EP1140171A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP99967362A 1998-12-15 1999-12-15 Methods and products for regulating lectin complement pathway associated complement activation Withdrawn EP1140171A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11239098P 1998-12-15 1998-12-15
PCT/US1999/029919 WO2000035483A1 (en) 1998-12-15 1999-12-15 Methods and products for regulating lectin complement pathway associated complement activation
US112390P 2008-11-07

Publications (2)

Publication Number Publication Date
EP1140171A1 EP1140171A1 (en) 2001-10-10
EP1140171A4 true EP1140171A4 (en) 2002-03-13

Family

ID=22343639

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99967362A Withdrawn EP1140171A4 (en) 1998-12-15 1999-12-15 Methods and products for regulating lectin complement pathway associated complement activation

Country Status (4)

Country Link
EP (1) EP1140171A4 (en)
JP (1) JP2002532079A (en)
CA (1) CA2347734A1 (en)
WO (1) WO2000035483A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
JP2003507338A (en) * 1999-08-13 2003-02-25 ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド Lectin complement pathway (LCP) inhibitors and uses thereof
NZ523900A (en) * 2000-07-13 2004-02-27 Jens Christian Jensenius Isolation and characterisation of a mannan-binding lectin (MBL) associated serine protease (MASP-2) and uses thereof to treat infections
EP1186299A1 (en) 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
EP2422812A1 (en) * 2003-02-21 2012-02-29 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Antibodies to masp-2
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8524453B2 (en) 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
EP3028716B1 (en) 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
CA2971474C (en) 2009-10-16 2022-11-22 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
ES2961381T3 (en) 2010-06-19 2024-03-11 Memorial Sloan Kettering Cancer Center Anti-GD2 antibodies
NZ709997A (en) 2011-04-08 2016-03-31 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
ME03755B (en) 2011-05-04 2021-04-20 Omeros Corp Compositions for inhibiting masp-2 dependent complement acitivation
RU2680267C2 (en) 2013-03-15 2019-02-19 Мемориал Слоан Кеттеринг Кэнсер Сентер High-affinity anti-gd2 antibodies
CN108588033B (en) * 2018-04-24 2021-09-24 富恩生物技术（成都）有限公司 Hybridoma cell strain, CD31 monoclonal antibody, preparation method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001519A1 (en) * 1987-08-20 1989-02-23 Children's Hospital Corporation Human mannose binding protein
WO1991006010A1 (en) * 1989-10-11 1991-05-02 Institute Of Child Health Diagnostic procedure
JPH06121695A (en) * 1992-10-13 1994-05-06 Fuji Yakuhin Kogyo Kk Antihuman mannose binding protein monoclonal antibody and its utilization
JPH07238100A (en) * 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd Monoclonal antibody to human masp

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
DE3927723A1 (en) * 1989-01-26 1990-08-02 Ulrich Prof Dr Speck N - ACETYL GLUCOSAMINE FOR BUCCAL USE
AU3881493A (en) * 1992-03-19 1993-10-21 University Of British Columbia, The Method and composition for suppression of side effects of anti-inflammatory drugs
US5998173A (en) * 1996-02-20 1999-12-07 The University Of Bristish Columbia Process for producing N-acetyl-D-glucosamine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001519A1 (en) * 1987-08-20 1989-02-23 Children's Hospital Corporation Human mannose binding protein
WO1991006010A1 (en) * 1989-10-11 1991-05-02 Institute Of Child Health Diagnostic procedure
JPH06121695A (en) * 1992-10-13 1994-05-06 Fuji Yakuhin Kogyo Kk Antihuman mannose binding protein monoclonal antibody and its utilization
JPH07238100A (en) * 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd Monoclonal antibody to human masp

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHAKA W ET AL: "Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of cryptococcus neoformans involves human mannose binding protein", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 159, 1997, pages 2979 - 2985, XP002145899, ISSN: 0022-1767 *
COLLARD C D ET AL: "ENDOTHELIAL REOXYGENATION ACTIVATES THE LECTIN COMPLEMENT PATHWAY: INHIBITION WITH ANTI-HUMAN MANNOSE BINDING LECTIN(MBL) THERAPY", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 36, no. 4/5, March 1999 (1999-03-01), pages 278, XP000944464, ISSN: 0026-895X *
COLLARD C D ET AL: "REOXYGENATION OF HYPOXIC HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS (HUVECS) ACTIVATES THE LECTIN COMPLEMENT PATHWAY (LCP)", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 12, no. 4, 17 March 1998 (1998-03-17), pages A29, XP000944437, ISSN: 0892-6638 *
ENDO M ET AL: "GLOMERULA DEPOSITION OF MANNOSE-BINDING LECTIN (MBL) INDICATES A NOVEL MECHANISM OF COMPLEMENT ACTIVATION IN IGA NEPHROPATHY", NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIVERSITY PRESS, GB, vol. 13, no. 8, 1998, pages 1984 - 1990, XP000874166, ISSN: 0931-0509 *
LHOTTA K ET AL: "GLOMERULAR DEPOSITION OF MANNOSE-BINDING LECTIN IN HUMAN GLOMERULONEPHRITIS", NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIVERSITY PRESS, GB, vol. 14, no. 4, April 1999 (1999-04-01), pages 881 - 886, XP000944395, ISSN: 0931-0509 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 410 (C - 1232) 2 August 1994 (1994-08-02) *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 01 31 January 1996 (1996-01-31) *
See also references of WO0035483A1 *
TENNER A J ET AL: "MANNOSE BINDING PROTEIN (MBP) ENHANCES MONONUCLEAR PHAGOCYTE FUNCTION VIA A RECEPTOR THAT CONTAINS THE 126,00 MR COMPONENT OF THE C1Q RECEPTOR", IMMUNITY, CELL PRESS, US, vol. 3, no. 4, 1 October 1995 (1995-10-01), pages 485 - 493, XP002058774, ISSN: 1074-7613 *
TERAI I ET AL: "ALPHA2-MACROGLOBULIN BINDS TO AND INHIBITS MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASE", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 7, no. 10, October 1995 (1995-10-01), pages 1579 - 1584, XP001034131, ISSN: 0953-8178 *

Also Published As

Publication number Publication date
EP1140171A1 (en) 2001-10-10
JP2002532079A (en) 2002-10-02
CA2347734A1 (en) 2000-06-22
WO2000035483A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
EP1140171A4 (en) Methods and products for regulating lectin complement pathway associated complement activation
IL137963A0 (en) Compositions and methods for regulating lymphocyte activation
GB2348808B (en) Methods and compositions for desensitisation
GB2352005B (en) Hinge and method
HU9900636D0 (en) Confectionery product and process
GB9808461D0 (en) Solid borate-diol interaction products
GB9715293D0 (en) Monitor and/or overload means
IL138207A0 (en) Methods and devices for modulating the immune response
LU90658B1 (en) Process for de-chlorinating and de-fouling oil
GB9615405D0 (en) Chocolate products
PL332631A1 (en) Spray-crystallised products and associated methods
GB2335288B (en) Holography apparatus, method and product
IL120554A (en) Kombucha products and processes for the preparation thereof
AU2752399A (en) Method for continuous casting and device for carrying out the method
HK1036273A1 (en) Pyridine derivative and pharmaceutical containing the same
EP1005277A4 (en) Dairy products with enhanced cla content
GB9717104D0 (en) Food products
ZA981366B (en) Sheathed continuously cast products
AU7764798A (en) Product and method for providing glutamine
AU6010998A (en) Method and device for the continuous cooking of pulp
GB9826121D0 (en) Products and methods
GB9823959D0 (en) Shaped food products
GB9825926D0 (en) Refractory products and their manufacture
GB9825250D0 (en) Products and processes therefor
GB0221730D0 (en) Food products

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010613

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020124

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 39/395 A, 7C 12N 5/06 B, 7C 12N 5/16 B, 7G 01N 33/50 B

17Q First examination report despatched

Effective date: 20020912

17Q First examination report despatched

Effective date: 20020912

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080529